tetano
Editor, Senior Moderator
Nat Immunol
. 2021 Nov 30.
doi: 10.1038/s41590-021-01088-9. Online ahead of print.
BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2
R Camille Brewer[SUP] 1 2 [/SUP], Nitya S Ramadoss[SUP] 1 2 [/SUP], Lauren J Lahey[SUP] 3 [/SUP], Shaghayegh Jahanbani[SUP] 1 2 [/SUP], William H Robinson[SUP] #[/SUP][SUP] 4 5 [/SUP], Tobias V Lanz[SUP] #[/SUP][SUP] 6 7 8 [/SUP]
Affiliations
Abstract
The first ever US Food and Drug Administration-approved messenger RNA vaccines are highly protective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SUP]1-3[/SUP]. However, the contribution of each dose to the generation of antibodies against SARS-CoV-2 spike (S) protein and the degree of protection against novel variants warrant further study. Here, we investigated the B cell response to the BNT162b2 vaccine by integrating B cell repertoire analysis with single-cell transcriptomics pre- and post-vaccination. The first vaccine dose elicits a recall response of IgA[SUP]+[/SUP] plasmablasts targeting the S subunit S2. Three weeks after the first dose, we observed an influx of minimally mutated IgG[SUP]+[/SUP] memory B cells that targeted the receptor binding domain on the S subunit S1 and likely developed from the naive B cell pool. This response was strongly boosted by the second dose and delivers potently neutralizing antibodies against SARS-CoV-2 and several of its variants.
. 2021 Nov 30.
doi: 10.1038/s41590-021-01088-9. Online ahead of print.
BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2
R Camille Brewer[SUP] 1 2 [/SUP], Nitya S Ramadoss[SUP] 1 2 [/SUP], Lauren J Lahey[SUP] 3 [/SUP], Shaghayegh Jahanbani[SUP] 1 2 [/SUP], William H Robinson[SUP] #[/SUP][SUP] 4 5 [/SUP], Tobias V Lanz[SUP] #[/SUP][SUP] 6 7 8 [/SUP]
Affiliations
- PMID: 34848871
- DOI: 10.1038/s41590-021-01088-9
Abstract
The first ever US Food and Drug Administration-approved messenger RNA vaccines are highly protective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SUP]1-3[/SUP]. However, the contribution of each dose to the generation of antibodies against SARS-CoV-2 spike (S) protein and the degree of protection against novel variants warrant further study. Here, we investigated the B cell response to the BNT162b2 vaccine by integrating B cell repertoire analysis with single-cell transcriptomics pre- and post-vaccination. The first vaccine dose elicits a recall response of IgA[SUP]+[/SUP] plasmablasts targeting the S subunit S2. Three weeks after the first dose, we observed an influx of minimally mutated IgG[SUP]+[/SUP] memory B cells that targeted the receptor binding domain on the S subunit S1 and likely developed from the naive B cell pool. This response was strongly boosted by the second dose and delivers potently neutralizing antibodies against SARS-CoV-2 and several of its variants.